Skip to main content
Sign in Create a free account
Varsity Tutors
Sign in

Biostatistical And Pharmacoeconomic Measures - NAPLEX

  1. In a comparative effectiveness trial, 420 adults (mean age 62 years; 52% female) with type 2 diabetes and established cardiovascular disease were randomized to Drug A vs Drug B for 24 weeks. The primary outcome (hemoglobin A1c reduction) was −1.1% with Drug A vs −0.9% with Drug B (mean difference −0.2%, 95% CI −0.35 to −0.05; p = 0.01). A cost analysis estimated total 24-week medication costs of $2,400 (Drug A) vs $1,800 (Drug B). What does the p-value indicate about the study results?
    Answer: If there were truly no difference between Drug A and Drug B, there is about a 1% probability of observing a difference at least this large due to random chance This question tests the interpretation of p-values in clinical trials. The key parameter is the p-value of 0.01 for the mean difference in hemoglobin A1c reduction. Choice B is the best interpretation because it correctly describes the p-value as the probability of observing the data (or more extreme) assuming the null hypothesis of no difference is true. Choice A is incorrect because the p-value does not represent the probability that one drug is clinically better; choice C misinterprets the result as applying to individual patients rather than the study population; choice D wrongly states that the confidence interval gives the probability of the true difference being exactly -0.2%. A p-value less than 0.05 indicates statistical significance, suggesting the observed difference is unlikely due to chance alone. In clinical decision-making, combine p-values with effect sizes and confidence intervals to assess practical importance.
  2. A comparative safety study in 2,400 patients (mean age 60 years; 45% female) with osteoarthritis compared NSAID AA vs NSAID BB for gastrointestinal bleeding over 6 months. Bleeding occurred in 1.8% (AA) vs 1.2% (BB), with relative risk 1.50 (95% CI 0.95 to 2.37; p = 0.08). What does the p-value indicate about the study results?
    Answer: If there were truly no difference in bleeding risk, there is about an 8% probability of observing a difference at least this large by chance This question tests p-value in NSAID safety studies. The key parameter is p=0.08 for relative risk of bleeding. Choice B is the best, accurately defining under null. Choice A claims causation; choice C misinterprets as probability for interval; choice D deems significant incorrectly. p=0.08 >0.05 lacks significance. Clinically, non-significant risks inform monitoring despite trends.
  3. A budget impact model evaluated formulary addition of a new long-acting injectable antipsychotic for schizophrenia in a Medicaid plan with 100,000 members. Eligible patients were 250 (mean age 36 years; 38% female), with 40% uptake. Pharmacy spending increased by $800,000 annually, and psychiatric hospitalizations decreased by 25 per year (average cost $18,000 each). What does the budget impact model suggest for the healthcare system over 1 year?
    Answer: Net increase of $350,000 because added pharmacy costs ($800,000) exceed avoided hospitalization costs ($450,000) This question examines budget impact for antipsychotic addition. The key parameter is the net increase from $800,000 pharmacy costs exceeding $450,000 avoided hospitalizations. Choice B is the best, accurately yielding $350,000 net increase. Choice A reverses to savings; choice C overstates savings; choice D dismisses modeling validity. Budget impact quantifies fiscal effects. Frameworks should include sensitivity analyses for uptake and cost variables.
  4. A meta-analysis pooled 6 trials (n = 4,100; mean age 50 years; 64% female) comparing an SSRI vs placebo for generalized anxiety disorder. The pooled response odds ratio was 1.40 (95% CI 1.15 to 1.70; p = 0.001). What is the primary conclusion from the meta-analysis?
    Answer: SSRIs significantly improve response compared with placebo This question evaluates meta-analysis on SSRIs for anxiety. The key parameter is the odds ratio of 1.40 (95% CI 1.15 to 1.70; p=0.001). Choice A is the best because the CI excludes 1.0, indicating significance. Choice B notes inclusion of 1.0 incorrectly; choice C misinterprets as worsening; choice D dismisses significance. Exclusion of 1.0 supports efficacy. Clinically, integrate with side effects for treatment decisions.
  5. A budget impact model evaluated adding a new inhaled triple therapy for COPD to a health plan with 50,000 covered lives. The eligible population was estimated at 600 patients (mean age 68 years; 55% male; frequent exacerbators). The model projected that 30% would switch to triple therapy, increasing pharmacy costs by $540,000 annually, while reducing COPD-related hospitalizations by 18 events per year (average cost $12,000 each). What does the budget impact model suggest for the healthcare system over 1 year?
    Answer: Net increase of $324,000 because added pharmacy costs ($540,000) exceed avoided hospitalization costs ($216,000) This question examines budget impact modeling for COPD therapy addition. The key parameter is the net financial impact from increased pharmacy costs of $540,000 and avoided hospitalization costs of $216,000. Choice B is the best as it correctly calculates a net increase of $324,000, reflecting higher overall costs. Choice A reverses the net impact direction; choice C ignores that models integrate outcomes and costs; choice D overstates savings by assuming total offset. Budget impact assesses short-term financial effects on a payer's budget. In decision frameworks, consider if clinical benefits justify net costs beyond one year.
  6. A cost-effectiveness analysis compared two smoking cessation strategies in adults (mean age 46 years; 51% female) with COPD: Strategy 1 (varenicline + counseling) vs Strategy 2 (nicotine patch + counseling). Over 1 year, Strategy 1 cost $820 and produced 0.78 QALYs; Strategy 2 cost $620 and produced 0.77 QALYs. Which treatment is most cost-effective at a willingness-to-pay threshold of $50,000 per QALY?
    Answer: Strategy 1, because the incremental cost-effectiveness ratio is $20,000 per QALY and is below $50,000 per QALY This question assesses cost-effectiveness in smoking cessation. The key parameter is the ICER of $20,000 per QALY for Strategy 1 versus 2. Choice B is the best because it falls below $50,000 per QALY. Choice A ignores ICER; choice C miscalculates ICER; choice D assumes automatic cost-saving. The ICER supports added value. Decision frameworks prioritize strategies with ICERs under thresholds for public health interventions.
  7. A cost-effectiveness analysis compared a new oral multiple sclerosis therapy (Drug U) vs an injectable (Drug V) in 2,000 adults (mean age 39 years; 72% female). Over 5 years, Drug U yielded 3.90 QALYs at $310,000, while Drug V yielded 3.80 QALYs at $290,000. Which treatment is most cost-effective at a willingness-to-pay threshold of $150,000 per QALY?
    Answer: Drug V, because Drug U's incremental cost-effectiveness ratio is $200,000 per QALY, which exceeds $150,000 per QALY This question assesses cost-effectiveness in multiple sclerosis therapy. The key parameter is the ICER of $200,000 per QALY for Drug U versus V. Choice C is the best because the ICER exceeds $150,000 per QALY, favoring V. Choice A prioritizes cost without QALYs; choice B misstates the ICER as below threshold; choice D ignores ICER evaluation. The ICER highlights poor value for small QALY gain. Use thresholds to balance efficacy and affordability in chronic disease management.
  8. A comparative trial enrolled 300 patients (mean age 59 years; 60% female) with rheumatoid arthritis on background methotrexate to receive Biologic M or Biologic N for 16 weeks. Clinical response occurred in 64% vs 55%, respectively (absolute difference 9%; 95% CI −2% to 20%; p = 0.11). Annual drug costs were $38,000 (M) vs $34,000 (N). How do the confidence intervals affect the interpretation of the study?
    Answer: Because the 95% CI includes 0, the difference in response is not statistically significant at the 0.05 level This question evaluates confidence interval interpretation in comparative trials. The key parameter is the 95% confidence interval (−2% to 20%) for the absolute difference in clinical response. Choice A is the best because the interval includes 0, indicating no statistically significant difference at the 0.05 level. Choice B is incorrect as negative values do not prove inferiority; choice C misapplies the interval to individual patients; choice D assumes clinical meaningfulness solely from the point estimate. The interval's inclusion of 0 aligns with p=0.11 >0.05. Clinically, non-significant results suggest considering costs, like $38,000 vs $34,000 annually, in treatment selection.
  9. In a trial of 800 patients (mean age 71 years; 51% female) with osteoporosis, Drug R reduced hip fractures compared with placebo: 2.0% vs 3.0% over 2 years (relative risk 0.67; p = 0.04). The absolute risk reduction was 1.0%. Drug R costs $900 per year, and a hip fracture hospitalization was estimated at $25,000. What does the p-value indicate about the study results?
    Answer: If Drug R truly had no effect, there is about a 4% probability of observing a difference at least this large by chance This question tests p-value interpretation in osteoporosis trials. The key parameter is the p-value of 0.04 for hip fracture reduction. Choice B is the best as it accurately defines the p-value under the null hypothesis. Choice A misstates it as the probability of no effect; choice C incorrectly applies to individual efficacy; choice D conflates significance with clinical and economic outcomes. A p=0.04 <0.05 indicates statistical significance. Clinically, pair p-values with absolute risk reduction (1.0%) to evaluate number needed to treat against costs like $900 per year.
  10. A budget impact model assessed adding a new migraine preventive injection for a plan with 200,000 members. Eligible patients were estimated at 1,000 (mean age 44 years; 78% female), with 20% uptake in year 1. The drug would add $1,800,000 in pharmacy costs, while reducing emergency department visits by 300 annually (average cost $900 each). What does the budget impact model suggest for the healthcare system over 1 year?
    Answer: Net increase of $1,530,000 because added pharmacy costs ($1,800,000) exceed avoided emergency department costs ($270,000) This question examines budget impact for migraine preventive therapy. The key parameter is the net impact from $1,800,000 added pharmacy costs and $270,000 avoided emergency department costs. Choice A is the best, calculating a net increase of $1,530,000 accurately. Choice B reverses the net calculation; choice C ignores cost integration; choice D assumes full offset unrealistically. Budget models forecast payer financial burden. Decision frameworks should project multi-year impacts to assess long-term sustainability.
  11. A cost-effectiveness evaluation compared Oral Anticoagulant Y vs warfarin for stroke prevention in nonvalvular atrial fibrillation among 10,000 patients (mean age 74 years; 46% female; 35% with prior stroke). Over a lifetime horizon, Anticoagulant Y produced 9.20 quality-adjusted life-years (QALYs) at a cost of $92,000, while warfarin produced 9.00 QALYs at a cost of $78,000. Based on these data, which treatment is most cost-effective at a willingness-to-pay threshold of $100,000 per QALY?
    Answer: Anticoagulant Y, because its incremental cost-effectiveness ratio is $70,000 per QALY and is below $100,000 per QALY This question assesses cost-effectiveness analysis using incremental cost-effectiveness ratios (ICERs). The key parameter is the ICER of $70,000 per QALY for Anticoagulant Y versus warfarin. Choice B is the best because the ICER falls below the $100,000 per QALY threshold, indicating Y is cost-effective. Choice A is suboptimal as it ignores QALY gains; choice C miscalculates warfarin's ICER; choice D is incorrect because higher QALYs do not automatically ensure cost-effectiveness without ICER evaluation. The ICER quantifies additional cost per unit of health benefit gained. In pharmacoeconomic decisions, compare ICERs to willingness-to-pay thresholds to guide resource allocation.
  12. A budget impact model assessed adopting a biosimilar monoclonal antibody for inflammatory bowel disease in a hospital system treating 400 patients (mean age 34 years; 57% female). The biosimilar was projected to capture 60% market share, lowering drug acquisition costs by $1,200 per patient-year compared with the reference product. One-time implementation costs (education, switching logistics) were $80,000 in year 1. What does the budget impact model suggest for the healthcare system over 1 year?
    Answer: Net savings of $208,000 because drug savings ($288,000) minus implementation costs ($80,000) equals $208,000 This question examines budget impact of biosimilar adoption. The key parameter is net savings from $288,000 drug savings minus $80,000 implementation costs. Choice A is the best, calculating $208,000 savings correctly. Choice B adds costs erroneously; choice C assumes costs outweigh savings; choice D denies modeling. Net savings support adoption. Frameworks assess one-time versus ongoing costs for sustainability.
  13. A comparative study in 500 adults (mean age 57 years; 53% male) with hypertension compared Drug S vs Drug T. Blood pressure control at 12 weeks was 72% vs 70% (absolute difference 2%; 95% CI −4% to 8%; p = 0.52). Monthly costs were $40 (S) vs $10 (T). How do the confidence intervals affect the interpretation of the study?
    Answer: The CI suggests the true difference could favor either drug, so a statistically significant difference was not demonstrated This question tests confidence interval effects in hypertension studies. The key parameter is the 95% CI (−4% to 8%) for blood pressure control difference. Choice A is the best because the interval includes 0, showing no significant difference (p=0.52>0.05). Choice B assumes superiority from point estimate alone; choice C misinterprets as probability for individuals; choice D wrongly infers inferiority. Inclusion of 0 suggests results could favor either drug. Clinically, non-significant findings emphasize cost differences ($40 vs $10 monthly) in therapy choice.
  14. A cost-effectiveness study compared an oral hepatitis C regimen (Regimen P) vs an older regimen (Regimen Q) in 1,200 adults (mean age 52 years; 40% female) with compensated cirrhosis. Sustained virologic response was 95% with P vs 90% with Q (p = 0.03). Total treatment cost was $24,000 for P vs $18,000 for Q, and the model estimated lifetime QALYs of 14.6 (P) vs 14.4 (Q). Which treatment is most cost-effective at a willingness-to-pay threshold of $50,000 per QALY?
    Answer: Regimen P, because its incremental cost-effectiveness ratio is $30,000 per QALY and is below $50,000 per QALY This question assesses cost-effectiveness in hepatitis C treatment. The key parameter is the ICER of $30,000 per QALY for Regimen P versus Q. Choice B is the best because the ICER is below the $50,000 per QALY threshold, favoring P. Choice A dismisses statistical significance without ICER context; choice C misattributes the ICER to Q; choice D wrongly links significance to cost-saving. The ICER reflects value from higher sustained virologic response. Use willingness-to-pay thresholds to determine if incremental benefits justify costs in resource-limited settings.
  15. A cost-effectiveness analysis compared two influenza vaccination strategies for adults aged 65 years and older (mean age 72 years; 55% female): high-dose vaccine vs standard-dose vaccine. Over one season, high-dose vaccine cost $62 and produced 0.8450 QALYs; standard-dose cost $32 and produced 0.8445 QALYs. Which treatment is most cost-effective at a willingness-to-pay threshold of $100,000 per QALY?
    Answer: High-dose vaccine, because the incremental cost-effectiveness ratio is $60,000 per QALY and is below $100,000 per QALY This question assesses cost-effectiveness in influenza vaccination. The key parameter is the ICER of $60,000 per QALY for high-dose versus standard. Choice A is the best because it is below $100,000 per QALY. Choice B prioritizes cost alone; choice C miscalculates ICER; choice D attributes wrong ICER. The ICER justifies added efficacy. Use seasonal models to guide elderly vaccination policies.
  16. A meta-analysis pooled 5 trials (n = 3,400; mean age 61 years; 48% female) comparing a proton pump inhibitor (PPI) deprescribing program vs usual care in older adults taking chronic PPIs. The pooled relative risk of recurrent reflux symptoms was 1.10 (95% CI 0.95 to 1.27; p = 0.20). The program reduced PPI costs by $60 per patient-year. What is the primary conclusion from the meta-analysis?
    Answer: Deprescribing does not show a statistically significant difference in recurrent symptoms compared with usual care This question evaluates meta-analysis on PPI deprescribing. The key parameter is the pooled relative risk of 1.10 (95% CI 0.95 to 1.27; p=0.20). Choice B is the best because the CI includes 1.0 and p>0.05, indicating no significant difference. Choice A claims significance without evidence; choice C misinterprets p=0.20 as benefit; choice D wrongly bases significance on excluding 0 instead of 1.0. Non-significance suggests deprescribing may not increase symptoms. Clinically, consider cost savings ($60 per patient-year) when risks are comparable.
  17. A meta-analysis pooled 10 studies (n = 9,800; mean age 56 years; 50% female) evaluating pharmacist-led medication therapy management (MTM) vs usual care in patients with uncontrolled hypertension. The pooled mean systolic blood pressure reduction was −4.5 mmHg (95% CI −6.0 to −3.0; p < 0.001). MTM cost $120 per patient-year to deliver and reduced cardiovascular-related hospitalizations by 0.01 per patient-year (estimated $15,000 per hospitalization). What is the primary conclusion from the meta-analysis?
    Answer: MTM significantly lowers systolic blood pressure compared with usual care This question evaluates meta-analysis on MTM in hypertension. The key parameter is the mean reduction of −4.5 mmHg (95% CI −6.0 to −3.0; p<0.001). Choice A is the best because the CI excludes 0, indicating significance. Choice B notes inclusion of 0 incorrectly; choice C misinterprets p as harm; choice D dismisses clinical relevance. Exclusion of 0 confirms effect. Clinically, weigh delivery costs ($120 per patient-year) against hospitalization reductions.
  18. A pharmacoeconomic analysis compared a new long-acting insulin (Insulin X) to standard basal insulin in 1,000 patients (median age 58 years; 49% female) with type 2 diabetes and chronic kidney disease stage 3. Over 1 year, severe hypoglycemia occurred in 6% with Insulin X vs 9% with standard insulin (relative risk 0.67; 95% CI 0.48 to 0.94; p = 0.02). Annual drug costs were $3,600 (Insulin X) vs $2,400 (standard), and each severe hypoglycemia event was estimated to cost $4,000 in medical care. How do the confidence intervals affect the interpretation of the study?
    Answer: Because the 95% CI does not include 1.0, the reduction in severe hypoglycemia with Insulin X is statistically significant This question evaluates the interpretation of confidence intervals in pharmacoeconomic analyses. The key parameter is the 95% confidence interval (0.48 to 0.94) for the relative risk of severe hypoglycemia. Choice A is the best conclusion because the interval does not include 1.0, indicating a statistically significant reduction at the 0.05 level. Choice B is incorrect as it overstates cost savings as guaranteed across all systems; choice C misapplies the confidence interval to individual patients rather than the population parameter; choice D wrongly interprets p=0.02 as evidence of underpowering. The confidence interval's exclusion of 1.0 supports rejecting the null hypothesis of no difference. When assessing clinical significance, consider both statistical results and economic factors like cost per event avoided.
  19. A budget impact model for a new oral COVID-19 antiviral evaluated a health plan with 1,000,000 members. In year 1, 5,000 high-risk patients (mean age 69 years; 52% female; 30% with chronic kidney disease) were expected to be treated. Drug cost was $530 per course, and hospitalization was reduced by 1.5 percentage points (from 6.0% to 4.5%); each COVID-19 hospitalization cost $20,000. What does the budget impact model suggest for the healthcare system over 1 year?
    Answer: Net increase of $1,150,000 because drug costs ($2,650,000) exceed avoided hospitalization costs ($1,500,000) This question examines budget impact for COVID-19 antiviral. The key parameter is net increase from $2,650,000 drug costs exceeding $1,500,000 avoided hospitalizations. Choice B is the best, calculating $1,150,000 increase accurately. Choice A uses wrong numbers; choice C reverses calculation; choice D denies conversion. Net increase informs budgeting. Frameworks include high-risk targeting to optimize impact.
  20. A comparative study of 900 patients (mean age 55 years; 58% female) with asthma compared Add-on Therapy C vs Add-on Therapy D for preventing exacerbations over 1 year. Exacerbation rates were 0.80 vs 0.90 per patient-year (rate ratio 0.89; 95% CI 0.80 to 0.99; p = 0.04). Annual drug costs were $3,200 (C) vs $2,600 (D). How do the confidence intervals affect the interpretation of the study?
    Answer: Because the 95% CI is entirely below 1.0, Therapy C shows a statistically significant reduction in exacerbation rate compared with Therapy D This question tests confidence intervals in asthma studies. The key parameter is the 95% CI (0.80 to 0.99) for exacerbation rate ratio. Choice A is the best because it is below 1.0, indicating significance. Choice B assumes cost justification; choice C misapplies to individuals; choice D dismisses due to proximity to 1.0. Exclusion of 1.0 confirms reduction. Clinically, assess against costs ($3,200 vs $2,600 annually).

Start this quiz